Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADCT Adc Therapeutics SA
- Stocks
- Healthcare
- NYSE: ADCT
Price (delayed)
$1.81
Market cap
$179.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$50.1M
adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Highlights
Adc Therapeutics's EPS has increased by 45% YoY and by 33% QoQ
The company's net income rose by 34% YoY and by 26% QoQ
Adc Therapeutics's equity has decreased by 37% YoY and by 18% from the previous quarter
Adc Therapeutics's quick ratio has decreased by 25% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of ADCT
Market
Valuations
Earnings
Shares outstanding
99.08M
Market cap
$179.34M
Enterprise value
$50.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.71
Revenue
$70.84M
Gross profit
$64.89M
Operating income
-$130.65M
Net income
-$157.85M
EBIT
-$107.47M
EBITDA
-$104.19M
Free cash flow
-$124.7M
Per share
Balance sheet
Liquidity
EPS
-$1.62
EPS diluted
-$1.62
Free cash flow per share
-$1.28
Book value per share
-$2.1
Revenue per share
$0.73
TBVPS
$3.31
Total assets
$321.98M
Total liabilities
$524.62M
Debt
$121.63M
Equity
-$202.64M
Working capital
$226.92M
Debt to equity
-0.6
Current ratio
3.82
Quick ratio
3.37
Net debt/EBITDA
1.24
Margins
Efficiency
Dividend
EBITDA margin
-147.1%
Gross margin
91.6%
Net margin
-222.8%
Operating margin
-184.4%
Return on assets
-46.7%
Return on equity
N/A
Return on invested capital
-83.8%
Return on capital employed
-44.5%
Return on sales
-151.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADCT stock price
How has the Adc Therapeutics stock price performed over time
Intraday
37.12%
1 week
42.52%
1 month
49.59%
1 year
-55.2%
YTD
-9.05%
QTD
28.37%
Financial performance
How have Adc Therapeutics's revenue and profit performed over time
Revenue
$70.84M
Gross profit
$64.89M
Operating income
-$130.65M
Net income
-$157.85M
Gross margin
91.6%
Net margin
-222.8%
Adc Therapeutics's net margin has increased by 35% YoY and by 26% QoQ
The company's net income rose by 34% YoY and by 26% QoQ
ADCT's operating margin is up by 23% year-on-year and by 6% since the previous quarter
Adc Therapeutics's operating income has increased by 21% YoY and by 5% QoQ
Price vs fundamentals
How does ADCT's price correlate with its fundamentals
Growth
What is Adc Therapeutics's growth rate over time
Valuation
What is Adc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.71
Adc Therapeutics's EPS has increased by 45% YoY and by 33% QoQ
Adc Therapeutics's equity has decreased by 37% YoY and by 18% from the previous quarter
ADCT's price to sales (P/S) is 42% lower than its last 4 quarters average of 4.3
Efficiency
How efficient is Adc Therapeutics business performance
Adc Therapeutics's return on sales has increased by 32% YoY and by 9% QoQ
The ROA has grown by 24% from the previous quarter and by 13% YoY
The return on invested capital has increased by 6% year-on-year and by 5% since the previous quarter
Dividends
What is ADCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADCT.
Financial health
How did Adc Therapeutics financials performed over time
Adc Therapeutics's total assets is 39% less than its total liabilities
Adc Therapeutics's quick ratio has decreased by 25% YoY and by 24% from the previous quarter
ADCT's current ratio is down by 23% year-on-year and by 22% since the previous quarter
Adc Therapeutics's debt is 160% higher than its equity
Adc Therapeutics's equity has decreased by 37% YoY and by 18% from the previous quarter
The debt to equity has grown by 28% YoY and by 17% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.